NSE · CURIS
Curis Lifesciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹20 Cr with net profit ₹3 Cr — a 14.72% net margin, versus 12.3% the period before.
Shareholding
As of 2026-03-31
- Promoter68.03%
- Public24.98%
- FII1.19%
- DII5.8%
340 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.74× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #68 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,44,717 Cr | 35.2 | 5.32 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,10,474 Cr | 22.63 | 4.07 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,09,707 Cr | 30.65 | 3.19 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,02,956 Cr | 94.15 | 19.43 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,154 Cr | 29.53 | 2.51 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹94,535 Cr | 25 | 2.49 | 9.25% | 10.7% |
| Lupin Limited | ₹93,511 Cr | 15.7 | 4.17 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹92,770 Cr | 43.48 | 5.7 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,016 Cr | 21.79 | 6.46 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹61,875 Cr | 27.15 | 4.49 | 16.66% | 14.31% |
| Curis Lifesciences Ltd.(this company) | ₹163 Cr | 30.47 | 4.36 | 0% | 13.16% |
AI analysis
AI-generated · google/gemini-2.5-flashCuris Lifesciences Ltd. has a market capitalization of Rs 91 Cr. The company reported revenue of Rs 49.65 Cr and an EPS of Rs 6.63. Its debt-to-equity ratio stands at 1.48.
Positives
- +Annual revenue has consistently increased from Rs 23.7619 Cr in March 2022 to Rs 49.645 Cr in March 2025.
- +Net profit has shown a consistent increase from Rs 0.4924 Cr in March 2022 to Rs 6.1051 Cr in March 2025.
- +Promoter holding is a substantial 68.032% as of March 31, 2026, indicating confidence in the business.
- +No promoter shares are reported as pledged.
Negatives
- −Return on equity (ROE) is 0% and return on capital employed (ROCE) is 0%.
- −The debt-to-equity ratio of 1.48 is relatively high.
- −The public shareholding increased from 7.3206% in October 2025 to 24.9779% in March 2026.
- −The company's profit margin is 0%.
Financial Performance
Annual revenue increased from Rs 35.889 Cr in March 2024 to Rs 49.645 Cr in March 2025. Net profit also rose from Rs 5.3565 Cr in March 2024 to Rs 6.1051 Cr in March 2025. EPS grew from Rs 107.13 in March 2024 to Rs 10.29 in March 2025.
Profitability & Returns
The company reported a P/E ratio of 49.56. Return on equity (ROE) is 0%, and return on capital employed (ROCE) is 0% based on the latest available data. The profit margin for the latest period is 0%.
Balance Sheet
Curis Lifesciences Ltd. has a book value of Rs 46.32 per share. The debt-to-equity ratio is 1.48, indicating a relatively high level of debt compared to equity.
Ownership & Pledges
Institutional holding stands at 6.9901%. There are no promoter pledges reported.
Data as of — price: 2026-09-17 · financials: Jun 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.